Business
Awarded two further contracts by Bicycle
Awarded two further contracts by Bicycle.
About this update from Physiomics Plc
[{"type":"text","content":"\n \n \n RNS Number : 7482E\n Physiomics PLC\n 03 March 2020\n \n \n \n \n \n 3 March 2020\n \n \n Physiomics plc \n \n \n (\"Physiomics\") or (the \"Company\")\n \n \n \n \n \n \n Physiomics awarded two further contracts by Bicycle Therapeutics\n \n \n \n \n Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded two further contracts of undisclosed value with its existing client Bicycle Therapeutics (\"Bicycle\"), building on the two projects announced in 2019.\n \n \n \n \n Last year Physiomics worked with Bicycle on BT1718, its lead programme currently in a Cancer Research UK-sponsored Phase I/IIa clinical in solid tumours. Physiomics' role related to the analysis of clinical data from this trial, and the Company's work was acknowledged in a poster presentation at the ESMO conference in September 2019(1). Separately, Physiomics also worked with Bicycle on the mathematical modelling of interactions between tumour and Bicycle compounds in an immune-oncology setting, which at the time of its announcement was the fourth project conducted by Physiomics in the immune-oncology space.\n \n \n \n \n The projects announced today will involve pharmacokinetic and pharmacodynamic analysis of a number of Bicycle compounds and build on work completed by the Company previously. Both projects are expected to be completed in the next six months.\n \n \n \n \n \n \n Dr Jim Millen, CEO said\n \n : \"We are delighted to be working with Bicycle Therapeutics again in 2020 and believe that we are contributing significantly to key development decisions. It is particularly interesting to be working with Bicycle at a time when it is forging close relationships with large cap pharma companies as evidenced by the recent announcement of a significant new deal with US giant Genentech(2)\"\n \n \n \n \n (1)https://www.bicycletherapeutics.com/wp-content/uploads/ESMO-Sep-2019-FINAL.pdf\n \n \n (2)https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-exclusive-strategic-collaboration\n \n \n \n \n Enquiries:\n &...